On December 18, 2025, the White House published this Executive Order (EO) regarding increasing medical marijuana and cannabidiol research. The EO directs the current presidential administration to complete the process for reclassifying marijuana under the federal Controlled Substances Act, moving it from Schedule I to Schedule III . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.


Latest Resources
See All
Negotiated reimbursement rates vary substantially across all American Society of Addiction Medicine (ASAM) Levels of Care for facility-based services—even after standardizing codes and removing outliers, according to a recent analysis released by the National Association of Addiction Treatment Providers (NAATP). The variation in reimbursement rates existed within and across payer networks, reflecting a fragmented and inequitable reimbursement environment rather than one driven by clinical outcomes, the report stated. The report outlines national commercial reimbursement patterns for Aetna, Blue Cross Blue Shield, Cigna, and United, including the Optum carrier networks.… Read